Regeneron's Dupixent Takes Another Step Toward Blockbuster Status
Regeneron Pharmaceuticals (NASDAQ: REGN) unveiled phase 3 study data for its autoimmune disease drug Dupixent earlier this week that show it is effective in treating asthma. The success has management planning to file for Dupixent's approval in asthma patients soon, and that suggests Dupixent could win an OK next year. If so, then this drug could end up on the fast track to becoming a billion-dollar drug.
An estimated $50 billion annually is spent directly caring for asthma patients, and a lot of that money goes toward paying for costly hospital care for patients suffering an asthma attack.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Teva Pharmaceutical Industries Ltd ADR Stock
€31.50
-1.250%
With 23 Buy predictions and not a single Sell prediction Teva Pharmaceutical Industries Ltd ADR is an absolute favorite of our community.
With a target price of 35 € there is a slightly positive potential of 11.11% for Teva Pharmaceutical Industries Ltd ADR compared to the current price of 31.5 €.
